CNCR
ETF Series Solutions Trust Range Cancer Therapeutics ETF
CNCR
CNCR
Delisted
CNCR was delisted on the 27th of May, 2025.
24 hedge funds and large institutions have $14.8M invested in ETF Series Solutions Trust Range Cancer Therapeutics ETF in 2021 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 3 increasing their positions, 8 reducing their positions, and 1 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
more funds holding in top 10
Funds holding in top 10: →
less ownership
Funds ownership: →
19% less capital invested
Capital invested by funds: $18.3M → $14.8M (-$3.47M)
63% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 8
Holders
24
Holding in Top 10
1
Calls
–
Puts
–
Top Buyers
| 1 | +$231K | |
| 2 | +$221K | |
| 3 | +$190K | |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$48K |
| 5 |
Fifth Third Bancorp
Cincinnati,
Ohio
|
+$46K |
Top Sellers
| 1 | -$1.5M | |
| 2 | -$760K | |
| 3 | -$478K | |
| 4 |
Citigroup
New York
|
-$108K |
| 5 |
LPL Financial
San Diego,
California
|
-$70.5K |